WESTMINSTER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH) today announced the appointment of Bruce
K. Bennett as Vice President, Manufacturing. In this position, Mr. Bennett
will lead the Company's manufacturing functions to support the continued
development and potential commercialization of Allos' product candidates.
"We are delighted to welcome Bruce to Allos," said Paul L. Berns,
President and CEO. "Bruce's experience in all aspects of pharmaceutical
manufacturing and his demonstrated leadership in the pharmaceutical,
biotechnology and life sciences industries will be valuable as we look to
advance our product candidates in support of our mission of developing and
commercializing promising new therapies for cancer patients."
Mr. Bennett has over 25 years of manufacturing experience in the
pharmaceutical, medical device and biotechnology industries. Since 2006,
Mr. Bennett has served as an independent consultant focused on the
development of business operations, technical and supply chain solutions
for biotechnology and pharmaceutical companies. From 2002 to 2006, Mr.
Bennett served as Vice President, Manufacturing at La Jolla
Pharmaceuticals, where he led a 50 member team in manufacturing, materials
management, vendor and commercial development, quality control, validation,
engineering, facilities, and environmental health and safety. Prior to La
Jolla, Mr. Bennett served as Vice President, Operations at Provasis
Therapeutics from 2000 to 2002, and as Vice President, Operations, RA/QA/QC
and Commercial Development at Via Medical Corporation from 1997 to 2000.
From 1987 to 1997, Mr. Bennett served as a senior operations executive of
various pharmaceutical, biotechnology and other companies. Mr. Bennett
earned his MBA from Pepperdine University and his B.S. in Industrial
Technology from California State University, Long Beach.
"I am very excited to join Allos and lead the Company's manufacturing
activities," said Mr. Bennett. "I believe Allos has the product candidates
and leadership team to make a potentially significant impact in the
development of new therapies for the treatment of cancer."
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on the
development and commercialization of small molecule therapeutics for the
treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating PDX in patients with non-small cell lung cancer and a range
of lymphoma sub-types. The Company's other product candidate is RH1, a
targeted chemotherapeutic agent currently being evaluated in a Phase 1
trial in patients with advanced solid tumors or non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's website at
http://www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
relating to Mr. Bennett's potential impact on the future growth and success
of the Company; the potential safety, efficacy and marketability of the
Company's product candidates; and other statements that are other than
statements of historical facts. In some cases, you can identify
forward-looking statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar
terminology or the negative of these terms, but their absence does not mean
that a particular statement is not forward-looking. Such forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties that may cause actual results to differ materially
from those anticipated by the forward-looking statements. These risks and
uncertainties include, among others, that the Company's product candidates
are in various stages of development and may never be fully developed in a
manner suitable for commercialization. If the Company is unable to develop,
receive approval for, or successfully commercialize any of its product
candidates, it will be unable to generate meaningful revenue from product
sales and may never become profitable. Additional information concerning
these and other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is contained in
the "Risk Factors" section of the Company's Annual Report on Form 10-K for
the year ended December 31, 2006 and in the Company's other periodic
reports and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently available to
the Company on the date hereof, and the Company undertakes no obligation to
revise or update these forward-looking statements to reflect events or
circumstances after the date of this release, except as required by law.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com/
CONTACT:
Derek Cole, Vice President, Investor
Relations of Allos Therapeutics, Inc., +1-720-540-5367,
dcole@allos.com
|
